Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Updated Oct 7, 2026
AI dilution summary: the dominant contractual driver and its mechanism, then each further driver ranked, for Signal8 Pro subscribers.
